A. Cox

Potential utility of p53 immunopositivity in differentiation of adenocarcinomas from reactive epithelial atypias of the lung.

P. Cagle, A. Fraire, R. Brown, 1996, Human pathology.

The lncRNA Fer1L4 is an adverse prognostic parameter in clear-cell renal-cell carcinoma

G. Kristiansen, Y. Tolkach, M. Ritter, 2020, Clinical and Translational Oncology.

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells

Gianpiero di Leva, M. Garofalo, Ammara Mehmood, 2021, Scientific Reports.

Identification of F-Box/SPRY Domain-Containing Protein 1 (FBXO45) as a Prognostic Biomarker for TMPRSS2–ERG-Positive Primary Prostate Cancers

G. Kristiansen, N. Klümper, M. Ritter, 2023, Cancers.

Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.

W. Weichert, K. Schwamborn, B. Wullich, 2023, European urology.

Otoferlin is a prognostic biomarker in patients with clear cell renal cell carcinoma: A systematic expression analysis

G. Kristiansen, J. Ellinger, Y. Tolkach, 2021, International journal of urology : official journal of the Japanese Urological Association.

Knockdown of Myoferlin Suppresses Migration and Invasion in Clear-Cell Renal-Cell Carcinoma

G. Kristiansen, D. Schmidt, Y. Tolkach, 2020, AntiCancer Research.

The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma.

G. Kristiansen, J. Ellinger, D. Schmidt, 2020, Urologic oncology.

Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center

J. Luetkens, A. Cox, J. Ellinger, 2024, BMC urology.

Early CRP kinetics to predict long‐term efficacy of first‐line immune‐checkpoint inhibition combination therapies in metastatic renal cell carcinoma: an updated multicentre real‐world experience applying different CRP kinetics definitions

C. Kalogirou, N. Klümper, A. Mattigk, 2023, Clinical & translational immunology.